Day: September 27, 2021

VANCOUVER, British Columbia, Sept. 27, 2021 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles revolutionizing the urban driving experience, has engaged investor relations specialists MZ Group (MZ) to manage a comprehensive, strategic investor relations and financial communications program across all key markets. MZ Group will work closely with ElectraMeccanica management to implement a comprehensive capital markets strategy focused on increasing the Company’s visibility in the investment community. The new campaign will highlight ElectraMeccanica’s transition to a commercial production enterprise with the upcoming sales deliveries and ramp of its flagship single-occupant SOLO electric vehicle (EV). The...

VANCOUVER, British Columbia, Sept. 27, 2021 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp (the “Company”) (SBB – TSX) reports changes to executive team effective September 27, 2021. After over 13 years with the Company, Elaine Bennett, Vice-President, Finance and CFO for the Company, will be stepping down from her role and moving on to pursue new opportunities. Ms. Wendy Louie will be assuming the position effective September 27, 2021. Ms. Louie is a Canadian Chartered Professional Accountant (CPA, CA) with over 25 years of diverse finance and leadership experience. She most recently has provided consulting services in the mining, shipping, energy and technology sectors through her private consulting company which included mergers and acquisitions, risk management and advisory expertise. She held a series of senior management...

Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022 LAVAL, Québec, Sept. 27, 2021 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of intravenous (IV) GTX-104 compared to currently marketed oral nimodipine capsules in 50 healthy subjects. The PK study is the next required step in the proposed 505(b)(2) regulatory pathway for GTX-104. Results from this study are expected in the first half of calendar 2022, and after review with the U.S. Food & Drug Administration (FDA), will help to determine the final design of the Company’s planned Phase 3 safety study for GTX-104 in Subarachnoid...

SCOTTSDALE, AZ, Sept. 27, 2021 (GLOBE NEWSWIRE) — AMMO, Inc. (Nasdaq: POWW & POWWP) (“AMMO” or the “Company”), a leading vertically integrated producer of high-performance ammunition and components and operator of GunBroker.com, the largest online marketplace serving the firearms and shooting sports industries, today announced it is increasing its prior fiscal second quarter $51 million revenue estimate to approximately $55 million for the period ending September 30, 2021. “The increase in our second fiscal quarter revenue estimate reflects continued momentum across our entire business,” said Fred Wagenhals, AMMO, Inc.’s Chairman and CEO. “Transaction activity at our leading marketplace platform, GunBroker.com, remains more robust, even when compared to last year’s record setting performance. We are also in the midst of implementing...

TORONTO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE: CLS) (TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced the release of its 2020 Sustainability Report. The report demonstrates Celestica’s commitment to fostering a company-wide culture of sustainability focused on supporting people, the planet and the communities in which it operates. Prepared in accordance with the GRI Standards, Celestica’s 2020 Sustainability Report can be viewed at www.celestica.com. “It is up to all of us to drive meaningful change if we are to succeed in mitigating climate change and supporting a more sustainable and inclusive world,” said Robert Ellis, Senior Vice President, Sustainability, and Chief Legal Officer, Celestica. “That important work remains...

Beyond Meat, Inc.Beyond Meat, Inc.Following this summer’s introduction of Beyond Chicken® Tenders in foodservice and successful launches of plant-based chicken at Panda Express and A&W Canada, Beyond Meat is debuting Beyond Chicken Tenders in prominent retail chains in select markets across the U.S., starting in October Beyond Meat is also increasing accessibility of its revolutionary plant-based offerings at Walmart, including a 70% increase in the number of stores offering Beyond Breakfast Sausage® Patties EL SEGUNDO, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) — Beyond Meat® (NASDAQ: BYND), a leader in plant-based meat, today announced that following multiple successful launches of its best-in-class plant-based chicken items in foodservice, it is debuting its Beyond Chicken® Tenders (MSRP: $4.99) at select...

FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (“PDS Biotech” or the “Company”, Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that its management will participate in the Benzinga Healthcare Small Cap Conference. PDS Biotech management will deliver a presentation providing an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on the progression of two investigational pipeline products PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1) into human clinical trials. Following the presentation, President and Chief Executive Officer of PDS Biotech, Dr. Frank Bedu-Addo, will join a panel of leading oncology experts discussing...

Company to Showcase Gourmet-Grade Pacific White Shrimp to Conference Attendees During Welcome Reception at Luxe Sunset Boulevard Hotel DALLAS, TX, Sept. 27, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), has been invited to present at the 14th Annual LD Micro Main Event being held on October 12-14, 2021 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. NaturalShrimp President and Chief Executive Officer Gerald Easterling, and Chief Financial Officer and Treasurer William Delgado will host in-person and virtual presentations during the conference and participate in one-on-one meetings, where they will discuss the Company’s recent...

MINNEAPOLIS, MN, Sept. 27, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Mitesco, Inc., (OTCQB: MITI) (“Mitesco” or the “Company”), a leading operator of primary care clinics that combine technology with relationship-driven, personalized healthcare, today announced the opening of its third Minnesota location of The Good Clinic in St. Louis Park.  “We are excited to extend whole-person healthcare to clients in the western Minneapolis suburbs through our new clinics in St. Louis Park and Eden Prairie,” said Larry Diamond, CEO of Mitesco. “We chose the St. Louis Park location because of its community resources, diverse population, and housing density, which enable its citizens to thrive. Our focus on convenience, value, and meeting peoples’ unique needs aligns well with the community.” The new St. Louis Park site is located at...

–  Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful –  Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21 Will Be Eligible to Enroll in Part B of MOMENTUM    CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter. MOMENTUM is a global trial investigating the use of SRP-5051, the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable...